argenx said on November 9 it had agreed to buy Unnatural Products for $550 million upfront, bringing an existing research partner under its control. Up to $595 million more depends on development and regulatory milestones, taking potential consideration to up to approximately $1.15 billion.
UNP develops experimental peptide medicines intended to be taken by mouth, combining AI-guided molecule design with laboratory synthesis and screening. Argenx says the technology could complement its antibody research and help it develop oral or long-acting treatments for immune diseases.
The companies announced a multi-target research pact in July 2025. Under that agreement, UNP would carry out early research on targets chosen by argenx, which held an exclusive option to develop and commercialize resulting medicines. Argenx already owns a minority stake and is buying the remaining shares.
UNP says it employs more than 50 people. Its team and leadership would stay in Santa Cruz after closing, with the site becoming argenx’s peptide-discovery hub. Both boards have approved the acquisition, which is expected to close by the end of 2026, subject to customary conditions.